CAS9 Technology Market Overview
CAS9 Technology Market is projected to grow from USD 3.96 Billion in 2024 to USD 8.38 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.82% during the forecast period (2024 - 2032). Additionally, the market size for CAS9 Technology was valued at USD 3.56 billion in 2023.
Increased awareness regarding biotechnology techniques and products and the increasing acceptance of gene therapy-based treatments are the major driving factors for the CAS9 technology market growth and are the key market drivers enhancing the market growth.
Figure 1: CAS9 Technology Market Size, 2024-2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
CAS9 Technology Market Trends
Growing investment and funding from the government are driving the market growth
There has been a notable increase in investment and funding from governments specifically directed towards CRISPR technology. This has created a conducive environment for research and development in the field, enabling breakthrough discoveries and propelling the market forward. For instance, in February 2023, Indian biotechnology start-up CrisprBits raised $250,000 in pre-seed funding from US-based VJ Group. The funding will be used to develop products, expand the team and invest in research and development. CrisprBits plans to develop CRISPR- based diagnostics to detect pathogens and antimicrobial resistance genes. This factor drives the market CAGR.
Additionally,the development of new vaccines and treatments for genetic diseases using CRISPR technology presents a transformative opportunity in the field of healthcare. CRISPR's precise gene editing capabilities hold immense potential in combating infectious diseases and addressing the underlying genetic causes of various disorders. This opportunity promises innovative approaches to prevent and treat diseases and revolutionizes how we approach healthcare interventions. For instance, Editas Medicine is conducting a phase 1/2 trial for individuals with severe sickle cell disease (SCD) but using a CRISPR system with a Cas12a protein rather than the more famous Cas9 protein. Moreover, Vertex Pharmaceuticals and CRISPR Therapeutics are working together on Beta-thalassemia. The clinical trial is in its second phase.
Furthermore, the quality of medicine can be significantly improved by using CRISPR technology to create a variety of medications. It can be utilised to create medications for cardiac conditions and blood issues. The market for CRISPR technology is expanding as a result of the technology's rising rate of adoption. The cost of CRISPR technology rises because to its complexity and sophisticated nature, further limiting its development. The increases in the availability of Government and private funding are the main reasons driving the market's growth. Furthermore, there is a rise in the number of cases of genetic disorders, and there is a need for advanced therapies such as CRISPR technology, which can be used to treat cancer, influencing market growth.Thus, driving the CAS9 Technology market revenue.
CAS9 Technology Market Segment Insights
CAS9 Technology Product Type Insights
Based on product type, the CAS9 Technology market segmentation includes consumables and vectors. The consumables segment dominated the market; consumables play a crucial role in the workflow and implementation of CAS9 technology. These include reagents, enzymes, and other essential components necessary for the CRISPR-Cas9 gene editing process. As CAS9 technology continues to gain prominence in various research and biotechnology applications, the demand for consumables rises accordingly.
CAS9 Technology Application Insights
The CAS9 Technology market segmentation, based on Application, includes genome engineering, disease models, and in vitro genetic depletion. The genome engineering segment dominated the market; the increasing adoption of CAS9 technology in academic and research institutions further strengthens the dominance of the Genome Engineering segment. Scientists and researchers across diverse disciplines recognize the power and versatility of CAS9 technology in studying gene functions, unraveling disease mechanisms, and exploring new avenues for discovery.
CAS9 Technology Delivery Method Insights
The CAS9 Technology market segmentation, based on delivery methods, includes physical delivery methods, viral delivery methods, and non-viral delivery method. The viral delivery methods segment dominated the market; viral delivery methods offer high efficiency in delivering the CRISPR-Cas9 components into target cells. Viral vectors, such as lentiviruses and adeno-associated viruses (AAVs), have evolved to efficiently infect many cell types, making them highly effective tools for gene editing applications. Their ability to deliver the CRISPR-Cas9 system to the desired cells ensures successful gene editing and manipulation.Furthermore, viral delivery methods benefit from their ability to achieve long-lasting gene expression and stable integration of the CRISPR-Cas9 system into the host cell's genome.
CAS9 Technology End User Insights
Based on end users, the CAS9 Technology market segmentation includes Biotechnology & Pharmaceutical Companies and Academic & Research Institutes. The biotechnology & pharmaceutical companies' segment dominated the market; the growing demand for innovative and targeted therapies is a major driver for pharmaceutical and biotechnology companies in the CRISPR market. CRISPR technology enables precise gene editing, offering the potential to develop personalized medicines for genetic diseases. North America was the largest market for the CRISPR industry in 2023.
Figure1: Global CAS9 Technology Market, byEnd User, 2022 & 2032(USD billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
CAS9 Technology Regional Insights
By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American CAS9 technology market will dominate due to strict regulations for manufacturing medical devices and providing medical services, which improves the quality of devices and technology and will boost the market growth in this Region.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure2: CAS9 TECHNOLOGY MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe CAS9 Technology market accounts for the second-largest market share due to theincreased investment in developing innovative solutions to treat genetic diseases by government-aided, run, and established bodies and centers. Further, the German CAS9 Technology market held the largest market share, and the UK CAS9 Technology market was the fastest-growing market in the European Region.
The Asia-Pacific CAS9 Technology Market is expected to grow at the fastest CAGR from 2023 to 2032. This is due tothe explanation of the biotechnology industry and the rapid implementation of advanced technologies, such as CAS9 is driving regional growth. Moreover, China’s CAS9 Technology market held the largest market share, and the Indian CAS9 Technology market was the fastest growing market in the Asia-Pacific region.
CAS9 Technology Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the CAS9 Technology market, grow even more. Market participants are also undertaking various strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the CAS9 Technology industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the CAS9 Technology industry to benefit clients and increase the market sector. The CAS9 Technology industry has offered some of the most significant medical advantages in recent years. Major players in the CAS9 Technology market, includingCellecta, Inc., abm Inc., GenScript, CRISPR Therapeutic, Intellia Therapeutics, Inc., GE Healthcare, Takara Bio, Inc., AstraZeneca, PLC, Merck KGaA, Bio-Rad Laboratories, Inc., Danaher Corporation (Integrated DNA Technologies, Inc.), New England Biolabs, OriGene Technologies, Inc., Lonza Group, and Thermo Fisher Scientific., and others, are attempting to increase market demand by investing in research and development operations.
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for various rare and common diseases. Using the gene-editing technique CRISPR/Cas9, CRISPR Therapeutics and Vertex Pharmaceuticals are extending their current partnership to create medicines for hereditary illnesses that cause muscular weakness.
A biotechnology business in the trial stages called Intellia treatments is dedicated to creating cutting-edge, possibly curative treatments using CRISPR-based technologies.Intellia Therapeutics and Novartis stated their relationship will be extended to encompass the ex vivo creation of novel cell treatments employing specific ocular stem cells.
Key Companies in the CAS9 Technology market include
-
ABM Inc.
-
-
CRISPR Therapeutic
-
Intellia Therapeutics Inc.
-
-
Takara Bio Inc.
-
-
PLC
-
Merck KGaA
-
Bio-Rad Laboratories Inc.
-
OriGene Technologies Inc.
-
Lonza Group
-
Thermo Fisher Scientific
CAS9 Technology Industry Developments
2024 saw a ten-year green power purchase agreement (PPA) being signed by Merck and China Resources Power Holdings Co., Ltd. It represents the first time Merck has bought renewable energy on a long-term basis in China, with an estimated consumption of 300 gigawatt-hours (GWh) within the next decade. This will reduce its Scope 2 carbon emissions by 185,000 tons and raise the company’s green power utilization to 60% during national production and operations.
Thermo Fisher Scientific showcased its commitment to helping customers bring medicines to patients faster by adding early development work for oral solid dose therapies at its site in Bourgoin, France, in 2023. This transfer will allow the site to manage customers’ workflow from early drug development up to commercial manufacturing.
The USFDA approved Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics’ CASGEVY as a CRISPR/Cas9 genome-edited cell therapy for treating sickle cell disease (SCD) in patients aged twelve years or more with recurrent vaso-occlusive crises (VOCs) in November 2023. It is the first-ever gene-editing therapy based on CRISPR that was approved by FDA.
In April 2022, Thermo Fisher Scientific launched Gibco CTS TrueCut Cas9 Protein; this high-quality Cas9 protein has consistent high editing efficiencies across cell lines and greater than 90% efficiency within human primary T-cells, therefore it is an ideal choice for researchers interested in CRISPR-based CAR T-cell therapy research.
In June 2021, QIAGEN introduced QIAprep& CRISPR Kit and CRISPR Q-Primer Solutions designed for rapid quantification of gene editing experiments, which measure DNA sequence function after intervention.
Thermo Fisher Scientific Inc: Development of GMP-manufactured Gibco CTS TrueCut Cas9 Protein supporting applications such as CAR T-cell therapy research and production.
Merck KGaA: CRISPR-based therapies for sickle cell disease and beta-thalassemia being studied at Merck KGaA.
Agilent Technologies Inc.: SureEdit CRISPR Genome Editing Kits – user-friendly kits for gene editing experiments.
Genscript Biotech Corp: offers customized CRISPR solutions, tailors its support to particular research schemes as well as development initiatives in the therapeutic area and enables pharmaceutical drug manufacturing.
Cellecta Limited: By using their proprietary CRISPR screening technologies, Cellecta can help you fast-track the identification of drug targets and therapeutic candidates.
2024 saw a ten-year green power purchase agreement (PPA) being signed by Merck and China Resources Power Holdings Co., Ltd. It represents the first time Merck has bought renewable energy on a long-term basis in China, with an estimated consumption of 300 gigawatt-hours (GWh) within the next decade. This will reduce its Scope 2 carbon emissions by 185,000 tons and raise the company’s green power utilization to 60% during national production and operations.
Thermo Fisher Scientific showcased its commitment to helping customers bring medicines to patients faster by adding early development work for oral solid dose therapies at its site in Bourgoin, France, in 2023. This transfer will allow the site to manage customers’ workflow from early drug development up to commercial manufacturing.
The USFDA approved Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics’ CASGEVY as a CRISPR/Cas9 genome-edited cell therapy for treating sickle cell disease (SCD) in patients aged twelve years or more with recurrent vaso-occlusive crises (VOCs) in November 2023. It is the first-ever gene-editing therapy based on CRISPR that was approved by FDA.
CAS9 Technology Market Segmentation
CAS9 Technology Products Type Outlook
CAS9 Technology Application Outlook
CAS9 Technology Delivery Method Outlook
CAS9 Technology Delivery End User Outlook
CAS9 Technology Regional Outlook
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Rest of Europe
-
Asia-Pacific
-
China
-
Japan
-
India
-
Australia
-
South Korea
-
Australia
-
Rest of Asia-Pacific
-
Rest of the World
-
Middle East
-
Africa
-
Latin America
| Report Attribute/Metric |
Details |
| Market Size 2023 |
USD 3.56 billion |
| Market Size 2024 |
USD 3.96 billion |
| Market Size 2032 |
USD 8.38 billion |
| Compound Annual Growth Rate (CAGR) |
9.82%(2024-2032) |
| Base Year |
2023 |
| Market Forecast Period |
2024-2032 |
| Historical Data |
2018- 2022 |
| Market Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Product Type,Application,Delivery Method, End User, and Region |
| Geographies Covered |
North America, Europe, AsiaPacific, and the Rest of the World |
| Countries Covered |
The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled |
abm Inc., GenScript, CRISPR Therapeutic, Intellia Therapeutics, Inc., GE Healthcare, Takara Bio, Inc., AstraZeneca, PLC, Merck KGaA, Bio-Rad Laboratories, Inc., Danaher Corporation (Integrated DNA Technologies, Inc.), New England Biolabs, OriGene Technologies, Inc., Lonza Group, and Thermo Fisher Scientific |
| Key Market Opportunities |
Obesity in children, healthier and more balanced diets |
| Key Market Dynamics |
Increase in health difficulties and worries, leading to costly operations |
CAS9 Technology Market Highlights:
Frequently Asked Questions (FAQ) :
The CAS9 Technology market size was valued at USD 3.56 Billion in 2023.
The market is projected to grow at a CAGR of 3.96% during the forecast period, 2024-2032.
North America had the largest share of the market
The key players in the market areABM Inc., GenScript, CRISPR Therapeutic, Intellia Therapeutics, Inc., GE Healthcare, Takara Bio, Inc., AstraZeneca, PLC, Merck KGaA, Bio-Rad Laboratories, Inc., Danaher Corporation (Integrated DNA Technologies, Inc.), New England Biolabs, OriGene Technologies, Inc.
The Consumables category dominated the market in 2022.
Genome Engineering had the largest share of the market.
